Vanguard deal on migraine drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.VANGUARD MEDICA, the biotechnology company, yesterday signed a $50m (pounds 29m) marketing deal for its star anti-migraine drug with the Irish pharmaceutical company Elan. Vanguard shares leapt 7.5p to 260p after Elan acquired the rights to distribute Frovatriptan in North America.
Elan also agreed to pay pounds 6m to buy a 3 per cent stake in Vanguard for pounds 6.25 a share. The deal ends Vanguard's six-month search for a partner for Frovatriptan, which is set to be launched next year. In May, SmithKline Beecham dropped the drug from its development programme, causing a collapse in Vanguard's share price.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments